{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:41Z","timestamp":1792839701475,"version":"4.5.0"},"reference-count":48,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100020621","name":"Volgograd State Medical University","doi-asserted-by":"crossref","award":["0123U100804"],"award-info":[{"award-number":["0123U100804"]}],"id":[{"id":"10.13039\/100020621","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>The outcomes of retreatment patients infected with hepatitis C virus genotype 3, cirrhosis, with velpatasvir may be affected by treatment failure with velpatasvir. The efficacy of SOF+GLE\/PIB+RIB 16\u201324 weeks of treatment has been shown. The presence of NS5A resistance-associated substitution mutations, including Y93H, and the number and regimens of the past failed therapy do not influence the likelihood of achieving sustained virological response. When velpatasvir treatment fails, pibrentasvir should be used as the first choice for retreatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/jvi.01843-24","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T14:00:28Z","timestamp":1737554428000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir\/pibrentasvir and ribavirin for 16\u201324 weeks"],"prefix":"10.1128","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5338-7072","authenticated-orcid":false,"given":"Sergii V.","family":"Fedorchenko","sequence":"first","affiliation":[{"name":"Department of Viral Hepatitis and AIDS, The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna","family":"Klimenko","sequence":"additional","affiliation":[{"name":"Department of Viral Hepatitis and AIDS, The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Martynovich","sequence":"additional","affiliation":[{"name":"Department of Viral Hepatitis and AIDS, The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Solianyk","sequence":"additional","affiliation":[{"name":"Department of Viral Hepatitis and AIDS, The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Suprunenko","sequence":"additional","affiliation":[{"name":"Department of Viral Hepatitis and AIDS, The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.03.429581"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000629"},{"key":"e_1_3_3_5_2","first-page":"270","volume-title":"Chronic HCV- infection","author":"Fedorchenko SV","year":"2010","unstructured":"Fedorchenko SV. 2010. Hronicheskay HCV- infekcia, p 270. In Chronic HCV- infection. Kiev Monograph VSI \u201cMedicina\u201d."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.08.001"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.03.014"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01441.x"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2019-002060"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.06.044"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15222"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz022"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14537"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14797"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13102096"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26935"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcvp.2023.100150"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13030432"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"e_1_3_3_21_2","unstructured":"The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. 2021. HCV guidance: recommendations for testing managing and treating hepatitis C. Available from: https:\/\/www.hcvguidelines.org\/"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.031"},{"key":"e_1_3_3_23_2","volume-title":"The Liver Meeting Digital Experience","author":"Weilert F","year":"2021","unstructured":"Weilert F, Tang H, Yao B, Lin M, Skoien R, Paik SW, Xie W, Morozov V, Tripathi R, Zhang Z, Burroughs M, Gane E. 2021. Retreatment of hepatitis C virus-infected patients who failed glecaprevir\/pibrentasvir. The Liver Meeting Digital Experience. AASLD - American Association for the Study of Liver Diseases"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13705"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/v11020148"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29837"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14797"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14592"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.03.004"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13038"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02158-6"},{"key":"e_1_3_3_32_2","volume-title":"The Liver Meeting","author":"Maio VCD","year":"2019","unstructured":"Maio VCD, Aragri M, Masetti C, Paolucci S, Bruzzone B, Degasperi E, Barbaliscia S, Pollicino T, Minichini C, Calvaruso V, et al.. 2019. Italian real life experience of resistance guided retreatment in HCV infected patients who previously failed a NS5A inhibitor containing regimen. The Liver Meeting. AASLD - American Association for the Study of Liver Diseases"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26971"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa304"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01249-18"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.10.034"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v14.i6.1248"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.06.042"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1652846"},{"key":"e_1_3_3_40_2","doi-asserted-by":"crossref","unstructured":"Gane E Faire B Helmy S Freeman J. 2022. Glecaprevir\/pibrentasvir & sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen. EASL.","DOI":"10.1016\/S0168-8278(22)00450-0"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30417-7"},{"key":"e_1_3_3_42_2","unstructured":"Saxena V McKinney J Scott L Catalli L Seo SI Ready GB Price JC Permanente K. 2021. Excellent efficacy and safety of sofosbuvir glecaprevir pibrentasvir and ribavirin for retreatment of chronic hepatitis C after sofosbuvir velpatasvir and voxilaprevir failureAASLD"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.017"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613512"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13067"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1217-7669"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13549"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1510"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100994"}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.01843-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jvi.01843-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T19:11:49Z","timestamp":1744312309000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jvi.01843-24"}},"subtitle":[],"editor":[{"given":"Stacey","family":"Schultz-Cherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,25]]}},"alternative-id":["10.1128\/jvi.01843-24"],"URL":"https:\/\/doi.org\/10.1128\/jvi.01843-24","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"2025-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01843-24"}}